Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Cash-to-Debt : 0.00 (As of Nov. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Cannabis Bioscience International Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cannabis Bioscience International Holdings's cash to debt ratio for the quarter that ended in Nov. 2023 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Cannabis Bioscience International Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Nov. 2023.

The historical rank and industry rank for Cannabis Bioscience International Holdings's Cash-to-Debt or its related term are showing as below:

CBIH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.04
Current: 0.04

During the past 5 years, Cannabis Bioscience International Holdings's highest Cash to Debt Ratio was 0.04. The lowest was 0.00. And the median was 0.00.

CBIH's Cash-to-Debt is ranked worse than
92.45% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs CBIH: 0.04

Cannabis Bioscience International Holdings Cash-to-Debt Historical Data

The historical data trend for Cannabis Bioscience International Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cannabis Bioscience International Holdings Cash-to-Debt Chart

Cannabis Bioscience International Holdings Annual Data

Trend

Dec06

Dec07

May09

May10

May11

Cash-to-Debt

1.43

No Debt

0.20

0.04

Cannabis Bioscience International Holdings Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	May09	Nov09	May10	Nov10	May11	Nov11	Nov22	Nov23
Cash-to-Debt	Get a 7-Day Free Trial							0.22	0.04	0.08	N/A	-

Competitive Comparison of Cannabis Bioscience International Holdings's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannabis Bioscience International Holdings's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Bioscience International Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cannabis Bioscience International Holdings's Cash-to-Debt falls into.

Cannabis Bioscience International Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cannabis Bioscience International Holdings's Cash to Debt Ratio for the fiscal year that ended in May. 2011 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.137	/	(3.171	+	0.516)
	=	0.04

Cannabis Bioscience International Holdings's Cash to Debt Ratio for the quarter that ended in Nov. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0	/	(0.222	+	0.283)
	=	0.00

Cannabis Bioscience International Holdings (OTCPK:CBIH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cannabis Bioscience International Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cannabis Bioscience International Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Bioscience International Holdings Inc (OTCPK:CBIH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

6201 Bonhomme Road, Suite 466S, Houston, TX, USA, 77036

Website

https://www.cbih.net

Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.